<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">37236416</PMID><DateRevised><Year>2023</Year><Month>07</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1555-7162</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>May</Month><Day>24</Day></PubDate></JournalIssue><Title>The American journal of medicine</Title><ISOAbbreviation>Am J Med</ISOAbbreviation></Journal><ArticleTitle>Prolonged Symptoms after COVID-19 in Japan: A Nationwide Survey of the Symptoms and Their Impact on Patients' Quality of Life.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0002-9343(23)00331-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjmed.2023.04.040</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Clinical details of long COVID are still not well understood because of potential confounding with a wide range of pre-existing comorbidities.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The present study used datasets from a nationwide, cross-sectional, online survey. We determined which prolonged symptoms were more likely to be associated with post-COVID condition after adjusting for a wide range of comorbidities and baseline characteristics. This study also used the EuroQol 5 Dimension 5 Level (EQ-5D-5L) and Somatic Symptom Scale-8 to assess health-related quality of life (QOL) and somatic symptoms in individuals with a previous history of COVID-19, defined as the diagnosis of COVID-19 made at least 2 months prior to the online survey.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 19,784 respondents were included for analysis; of these, 2397 (12.1%) had a previous history of COVID-19. The absolute difference of adjusted prevalence of symptoms attributed to prolonged symptoms after COVID-19 ranged from -0.4% to +2.0%. Headache (adjusted odds ratio [aOR]: 1.22; 95% confidence interval [95% CI]:1.07-1.39), chest discomfort (aOR:1.34, 95% CI:1.01-1.77), dysgeusia (aOR: 2.05, 95% CI: 1.39-3.04), and dysosmia (aOR: 1.96, 95% CI: 1.35-2.84) were independently associated with a previous history of COVID-19. Individuals with a previous history of COVID-19 had lower health-related QOL scores.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">After adjusting for potential comorbidities and confounders, clinical symptoms, such as headache, chest discomfort, dysgeusia, and dysosmia, were found to be independently associated with a previous history of COVID-19, which was diagnosed 2 or more months previously. These protracted symptoms might have impacted QOL and the overall somatic symptom burden in subjects with a previous history of COVID-19.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Honda</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Fujita Health University School of Medicine, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takamatsu</LastName><ForeName>Akane</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miwa</LastName><ForeName>Toshiki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, The University of Tokyo Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tabuchi</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cancer Control Center, Osaka International Cancer Institute, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taniguchi</LastName><ForeName>Kiyosu</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Hospital Organization, Mie Medical Center, Japan; Tokyo Foundation for Policy Research, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shibuya</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Tokyo Foundation for Policy Research, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tokuda</LastName><ForeName>Yasuharu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Tokyo Foundation for Policy Research, Japan; Muribushi Okinawa Center for Teaching Hospitals, Japan.. Electronic address: yasuharu.tokuda@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med</MedlineTA><NlmUniqueID>0267200</NlmUniqueID><ISSNLinking>0002-9343</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Prolonged symptoms</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">Somatic symptoms</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37236416</ArticleId><ArticleId IdType="pmc">PMC10208656</ArticleId><ArticleId IdType="doi">10.1016/j.amjmed.2023.04.040</ArticleId><ArticleId IdType="pii">S0002-9343(23)00331-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carfi A, Bernabei R, Landi F. Gemelli Against C-P-ACSG. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324(6):603&#x2013;605. doi: 10.1001/jama.2020.12603. Aug 11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Post COVID-19 condition (Long COVID). https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition Last accessed 02052023</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. Jan 13 2023:1&#x2013;14. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. Nov 1 2022;226(9):1593&#x2013;1607. doi: 10.1093/infdis/jiac136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, et al. Prevalence and Correlates of Long COVID Symptoms Among US Adults. JAMA Netw Open. Oct 3 2022;5(10) doi: 10.1001/jamanetworkopen.2022.38804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.38804</ArticleId><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long CC. Wulf Hanson S, Abbafati C, et al. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA. Oct 25 2022;328(16):1604&#x2013;1615. doi: 10.1001/jama.2022.18931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwan NA, Johnson L. Defining long COVID: Going back to the start. Med (N Y) May 14 2021;2(5):501&#x2013;504. doi: 10.1016/j.medj.2021.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2021.03.003</ArticleId><ArticleId IdType="pmc">PMC7992371</ArticleId><ArticleId IdType="pubmed">33786465</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. Aug 2022;28(8):1706&#x2013;1714. doi: 10.1038/s41591-022-01909-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>JACSIS study. JACSIS study. https://jacsis-study.jp/about/Last accessed 02052023</Citation></Reference><Reference><Citation>Rakuten Insight. Rakuten Insight internet search https://insight.rakuten.co.jp/en/aboutus.html. Last accessed 02052023</Citation></Reference><Reference><Citation>Lubetkin EI, Long D, Haagsma JA, Janssen MF, Bonsel GJ. Health inequities as measured by the EQ-5D-5L during COVID-19: Results from New York in healthy and diseased persons. PLoS One. 2022;17(7) doi: 10.1371/journal.pone.0272252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0272252</ArticleId><ArticleId IdType="pmc">PMC9333246</ArticleId><ArticleId IdType="pubmed">35901071</ArticleId></ArticleIdList></Reference><Reference><Citation>Gierk B, Kohlmann S, Kroenke K, et al. The somatic symptom scale-8 (SSS-8): a brief measure of somatic symptom burden. JAMA Intern Med. Mar 2014;174(3):399&#x2013;407. doi: 10.1001/jamainternmed.2013.12179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2013.12179</ArticleId><ArticleId IdType="pubmed">24276929</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(30):993&#x2013;998. doi: 10.15585/mmwr.mm6930e1. Jul 31.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson EJ, Williams DM, Walker AJ, et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. Jun 28 2022;13(1):3528. doi: 10.1038/s41467-022-30836-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30836-0</ArticleId><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. Jul 2022;28(7):1461&#x2013;1467. doi: 10.1038/s41591-022-01840-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. Jul 26 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M, Braillard O, Alcoba G, et al. COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings. Ann Intern Med. May 2021;174(5):723&#x2013;725. doi: 10.7326/M20-5926.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-5926</ArticleId><ArticleId IdType="pmc">PMC7741180</ArticleId><ArticleId IdType="pubmed">33284676</ArticleId></ArticleIdList></Reference><Reference><Citation>H L. How common is long COVID? Why studies give different answers. 2023 https://www.nature.com/articles/d41586-022-01702-2 Last accessed.</Citation><ArticleIdList><ArticleId IdType="pubmed">35725828</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevention CfDCa. Post-COVID Conditions: Information for Healthcare Providers. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html Last accessed 02052023.</Citation></Reference><Reference><Citation>Saunders C, Sperling S, Bendstrup E. A new paradigm is needed to explain long COVID. Lancet Respir Med. Jan 5 2023 doi: 10.1016/S2213-2600(22)00501-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00501-X</ArticleId><ArticleId IdType="pubmed">36620963</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Ailshire JA, Crimmins EM. Long COVID and symptom trajectory in a representative sample of Americans in the first year of the pandemic. Sci Rep. Jul 8 2022;12(1):11647. doi: 10.1038/s41598-022-15727-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-15727-0</ArticleId><ArticleId IdType="pmc">PMC9264749</ArticleId><ArticleId IdType="pubmed">35804058</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AW, Shah AS, Johnston JC, Carlsten C, Ryerson CJ. Patient-reported outcome measures after COVID-19: a prospective cohort study. Eur Respir J. Nov 2020;56(5) doi: 10.1183/13993003.03276-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.03276-2020</ArticleId><ArticleId IdType="pmc">PMC7530908</ArticleId><ArticleId IdType="pubmed">33008936</ArticleId></ArticleIdList></Reference><Reference><Citation>Soh HS, Cho B. Long COVID-19 and Health-Related Quality of Life of Mild Cases in Korea: 3-Months Follow-up of a Single Community Treatment Center. J Korean Med Sci. Nov 28 2022;37(46):e326. doi: 10.3346/jkms.2022.37.e326.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2022.37.e326</ArticleId><ArticleId IdType="pmc">PMC9705205</ArticleId><ArticleId IdType="pubmed">36631024</ArticleId></ArticleIdList></Reference><Reference><Citation>Walle-Hansen MM, Ranhoff AH, Mellingsaeter M, Wang-Hansen MS, Myrstad M. Health-related quality of life, functional decline, and long-term mortality in older patients following hospitalisation due to COVID-19. BMC Geriatr. Mar 22 2021;21(1):199. doi: 10.1186/s12877-021-02140-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-021-02140-x</ArticleId><ArticleId IdType="pmc">PMC7983098</ArticleId><ArticleId IdType="pubmed">33752614</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-de-Las-Penas C, Rodriguez-Jimenez J, Moro-Lopez-Menchero P, et al. Psychometric properties of the Spanish version of the EuroQol-5D-5L in previously hospitalized COVID-19 survivors with long COVID. Sci Rep. Jul 23 2022;12(1):12605. doi: 10.1038/s41598-022-17033-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-17033-1</ArticleId><ArticleId IdType="pmc">PMC9307967</ArticleId><ArticleId IdType="pubmed">35871259</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bosworth ML, King S, et al. Risk of Long COVID in People Infected With Severe Acute Respiratory Syndrome Coronavirus 2 After 2 Doses of a Coronavirus Disease 2019 Vaccine: Community-Based, Matched Cohort Study. Open Forum Infect Dis. Sep 2022;9(9):ofac464. doi: 10.1093/ofid/ofac464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac464</ArticleId><ArticleId IdType="pmc">PMC9494414</ArticleId><ArticleId IdType="pubmed">36168555</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B, Sudry T, Flaks-Manov N, et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. Jan 11 2023;380 doi: 10.1136/bmj-2022-072529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072529</ArticleId><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>